JP2025513240A - 慢性肺同種移植片機能不全を治療するためのベルモスジル - Google Patents

慢性肺同種移植片機能不全を治療するためのベルモスジル Download PDF

Info

Publication number
JP2025513240A
JP2025513240A JP2024560674A JP2024560674A JP2025513240A JP 2025513240 A JP2025513240 A JP 2025513240A JP 2024560674 A JP2024560674 A JP 2024560674A JP 2024560674 A JP2024560674 A JP 2024560674A JP 2025513240 A JP2025513240 A JP 2025513240A
Authority
JP
Japan
Prior art keywords
subject
belmosudil
pulmonary
nih
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513240A5 (https=
Inventor
コーリー・エス・カトラー
ザッカライアー・マイケル・デフィリップ
ヘスク・ティー・キム
Original Assignee
カドモン コーポレイション，リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カドモン コーポレイション，リミティド ライアビリティ カンパニー filed Critical カドモン コーポレイション，リミティド ライアビリティ カンパニー
Publication of JP2025513240A publication Critical patent/JP2025513240A/ja
Publication of JP2025513240A5 publication Critical patent/JP2025513240A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024560674A 2022-04-19 2023-04-18 慢性肺同種移植片機能不全を治療するためのベルモスジル Pending JP2025513240A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263332628P 2022-04-19 2022-04-19
US63/332,628 2022-04-19
US202263389444P 2022-07-15 2022-07-15
US63/389,444 2022-07-15
PCT/US2023/018952 WO2023205153A1 (en) 2022-04-19 2023-04-18 Belumosudil for treating chronic lung allograft dysfunction

Publications (2)

Publication Number Publication Date
JP2025513240A true JP2025513240A (ja) 2025-04-24
JP2025513240A5 JP2025513240A5 (https=) 2026-04-27

Family

ID=86330932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560674A Pending JP2025513240A (ja) 2022-04-19 2023-04-18 慢性肺同種移植片機能不全を治療するためのベルモスジル

Country Status (11)

Country Link
US (1) US20250255867A1 (https=)
EP (1) EP4511036A1 (https=)
JP (1) JP2025513240A (https=)
KR (1) KR20250003657A (https=)
CN (1) CN119031914A (https=)
AU (1) AU2023256541A1 (https=)
CA (1) CA3249201A1 (https=)
IL (1) IL316410A (https=)
MX (1) MX2024012802A (https=)
TW (1) TW202404602A (https=)
WO (1) WO2023205153A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325938A (en) * 2023-07-17 2026-03-01 Kadmon Corp Llc Combination therapy including BTK inhibitor and BELUMOSUDIL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
CN113620933A (zh) 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
US11311541B2 (en) * 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD

Also Published As

Publication number Publication date
WO2023205153A1 (en) 2023-10-26
US20250255867A1 (en) 2025-08-14
CN119031914A (zh) 2024-11-26
TW202404602A (zh) 2024-02-01
AU2023256541A1 (en) 2024-12-05
CA3249201A1 (en) 2023-10-26
IL316410A (en) 2024-12-01
EP4511036A1 (en) 2025-02-26
MX2024012802A (es) 2024-11-08
KR20250003657A (ko) 2025-01-07
AU2023256541A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
KR102495432B1 (ko) 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
US20260103532A1 (en) Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof
KR20250088633A (ko) (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여하여 면역 혈소판 감소증을 치료하는 방법
Zhao et al. A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or-dependent chronic GVHD
JP2025513240A (ja) 慢性肺同種移植片機能不全を治療するためのベルモスジル
JP2024153734A (ja) 肺動脈性肺高血圧症の治療方法
JP2026505367A (ja) 高タンパク尿慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの合剤
US20260027116A1 (en) Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Pidala et al. Carfilzomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium pilot phase II trial
Fujino et al. Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension
RAPOR Acute eosinophilic pneumonia secondary to heroin inhalation
Kumar et al. Electrocardiographic abnormalities in patients with acute exacerbation of chronic obstructive pulmonary disease
US20250352520A1 (en) Use of dexpramipexole for the treatment of eosinophilic copd
Heriot et al. Ocular involvement in a patient with L egionella longbeachae 1 infection
Yoshino et al. Surgical treatment of secondary pneumothorax-complicated interstitial lung disease
Lafian et al. A 40-Year-Old Female With Facial Rash and Persistent Cough
JP2025523818A (ja) 慢性移植片対宿主疾患の治療のためのベルモスジルの投与方法
TW202535375A (zh) 苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途
Phillips et al. COVID-19 Case Complicated with Organizing Pneumonia and Pneumothorax: A Case Report
Hossain et al. Modified D2 Gastrectomy operation in Gastric Cancer Patients and Outcome
Patil et al. Case Report with Review of Literature: Combined Pulmonary Fibrosis with Emphysema (CPFE)-Case Report
Baughman et al. Postgraduate Course ERS Copenhagen 2005-Therapeutic options for interstitial lung diseases in 2005
WO2025184133A1 (en) Methods of treating chronic graft versus host disease with belumosudil after ceasing administration of ruxolitinib
Garg et al. Case Report Follicular Bronchiolitis: Two Cases with Varying Clinical and Radiological Presentation
JP2025541153A (ja) リルザブルチニブを投与することによる認知障害を有する対象における免疫性血小板減少症の治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260417